GOLDEN BRIDGE II: AI-Supported Stroke Care Reduces Vascular Events Across 77 Hospitals
Evidence: Multicenter cluster-randomized clinical trial
Original study published: . This MedXchange brief was published on 2026-10-26.
Study Design and Methods
The BMJ cluster-randomized trial enrolled 21,603 patients with acute ischemic stroke across 77 hospitals in China. Hospitals were allocated to decision support or usual care. The primary endpoint was a new vascular event within three months. Because the intervention included several linked clinical functions, its effect estimate applies to the package delivered by the participating hospitals. The design does not assign that effect to any individual component.
Key Findings
At three months, vascular events occurred in 2.9% of the intervention group and 3.9% of controls: adjusted hazard ratio 0.74, 95% CI 0.58–0.93; P=0.01.
At 12 months, rates were 4.0% and 5.5%: adjusted hazard ratio 0.73, 95% CI 0.56–0.95; P=0.02.
Disability and all-cause mortality did not differ significantly.
Clinical Significance
A vascular-event endpoint gives the trial a different clinical meaning from a study reporting only diagnostic accuracy. The relevant observation is that outcomes differed after introduction of the complete decision-support pathway. The absolute event rates and adjusted hazard ratios convey complementary information. The rates describe the observed burden over the reported period; the hazard ratios estimate a relative time-to-event association under the study's analysis. They should not be treated as interchangeable measures.
Clinical Interpretation
The interpretation is strongest when it remains tied to what was randomized. Hospital allocation reflects the institutional setting in which care was delivered, and the adjusted analysis accounts for the study structure. A simple division of patient-level event counts does not reproduce that estimate. The clinical result supports examination of integrated decision support in stroke care. It does not establish that purchasing the imaging component alone, or deploying a different combination of software functions, would produce the same outcome.
Limitations
This was a bundled intervention evaluated in a specific health-system setting. The separate contribution of AI imaging, etiological classification and treatment recommendations cannot be resolved from the package comparison. The vascular-event findings should not be extended into a demonstrated disability or mortality benefit.
Explore the Work Behind Clinical AI
MedXchange Research Fellowship
Publish Clinical AI Research With Us
Our 10-week fellowship mentors physicians and researchers to build foundation models, analyze multimodal health datasets, and co-author peer-reviewed clinical studies.
Related Clinical AI Stories
UK NHS Expands Stroke AI Brain-Imaging Network to 110 Acute Emergency Centers
The UK National Health Service (NHS) has published a 2-year nationwide clinical audit on the deployment of deep learning stroke imaging algorithms across 110 acute hospital trusts. Reported by BBC News Health, the real-world data demonstrates that automated AI analysis of non-contrast CT and CT angiography scans tripled the rate of rapid thrombectomy referrals and reduced door-to-treatment decision times by over 60 minutes. By enabling instant mobile sharing of 3D brain perfusion maps between frontline emergency physicians and on-call interventional neurosurgeons, the network has prevented severe permanent neurological disability in thousands of ischemic stroke patients.
AI's Role in Diagnosing Rare and Undiagnosed Diseases: A Critical Perspective
A recent perspective from the NEJM Catalyst Insights Council highlights the significant potential of artificial intelligence (AI) in accelerating the diagnosis of rare and undiagnosed diseases. These conditions, often individually uncommon, collectively affect a substantial patient population, leading to prolonged diagnostic odysseys, increased healthcare costs, and significant patient morbidity. The Council emphasizes that while AI offers unprecedented capabilities in pattern recognition across vast datasets, it represents only one component of a multifaceted solution required to address this complex clinical challenge. The editorial underscores that the inherent complexity of rare diseases—characterized by phenotypic heterogeneity, genetic variability, and limited epidemiological data—makes them particularly amenable to AI's strengths in identifying subtle correlations and anomalies. However, achieving accurate and timely diagnoses will necessitate more than just technological advancements; it demands integrated strategies encompassing robust data infrastructure, multidisciplinary clinical collaboration, and careful consideration of ethical implications.
LLM Chatbot Offers Promising, Yet Flawed, Allergen Avoidance Guidance in Contact Dermatitis
A recent quantitative evaluation study explored the utility of a Large Language Model (LLM) chatbot, specifically GPT-4, in providing allergen-free product recommendations for patients with contact dermatitis. The study assessed the LLM's ability to recommend products free of 30 common allergen groups found in international standard patch tests. While the chatbot demonstrated a high proportion of valid responses, particularly for cosmetics and medications, clinicians must recognize its limitations, especially concerning complex allergens prone to cross-reactivity. Over a period from September 2023 to January 2024, GPT-4 was prompted to suggest five allergen-free products for each allergen group, utilizing three distinct question formats. Dermatologists manually reviewed and categorized 2250 responses for validity, invalidity, cross-reactions, unknown status, and unresponsiveness. The findings indicate a significant potential for LLM tools to assist in allergen avoidance counseling, albeit with a crucial need for human verification and oversight.